Expression did not change during endocrine treatment and may predict the
Expression did not change during endocrine treatment and may predict the effects of anastrozole and tamoxifen in postmenopausal BC patients. These effects of hormonal treatment on cell proliferationMadeira et al. BMC Cancer 2013, 13:425 http://www.biomedcentral.com/1471-2407/13/Page 11 of5.6. 7. 8.9.10.11. 12.13.14.15.16.17.18.19. 20.21.22.23.24.25.Hurvitz SA, Pietras RJ: Rational Actidione clinical trials management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008, 113(9):2385?397. Jones KL, Buzdar AU: A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 2004, 11(3):391?06. Pearce ST, Jordan VC: The biological role of estrogen receptors alpha and beta in cancer. Crit Rev Oncol Hematol 2004, 50(1):3?2. Shaaban AM, Sloane JP, West CR, Foster CS: Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression. Am J Pathol 2002, 160(2):597?04. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS, et al: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005, 365(9453):60?2. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA: Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996, 93(12):5925?930. Fox EM, Davis RJ, Shupnik MA: ERbeta in breast cancer nlooker, passive player, or active protector? Steroids 2008, 73(11):1039?051. Strom A, Hartman J, Foster JS, Kietz S, Wimalasena J, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/26577270 Gustafsson JA: Estrogen receptor beta inhibits 17beta-estradiol-stimulated proliferation of the breast cancer cell line T47D. Proc Natl Acad Sci U S A 2004, 101 (6):1566?571. Lazennec G, Bresson D, Lucas A, Chauveau C, Vignon F: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142(9):4120?130. Paruthiyil PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28724915 S, Parmar H, Kerekatte V, Cunha GR, Firestone GL, Leitman DC: Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res 2004, 64(1):423?28. Rayner K, Chen YX, Hibbert B, White D, Miller H, Postel EH, O’Brien ER: Discovery of NM23-H2 as an estrogen receptor beta-associated protein: role in estrogen-induced gene transcription and cell migration. J Steroid Biochem Mol Biol 2008, 108(1?):72?1. Hartman J, Lindberg K, Morani A, Inzunza J, Strom A, Gustafsson JA: Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. Cancer Res 2006, 66(23):11207?1213. Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, Matsuura M, Ito Y, Akiyama F, Sakamoto G: Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol 2008, 26(22):3727?734. Lindberg K, Helguero LA, Omoto Y, Gustafsson JA, Haldosen LA: Estrogen receptor beta represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity. Breast Cancer Res 2011, 13(2):R43. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 1998, 51(3):227?38. Hodges-Gallagher L, Valentine CD, El Bader S, Kushner PJ: Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells. Breast Cancer Res Treat 2008, 1.
